A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 32 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] 30 kg/m2 or more, or BMI 27 kg/m2 or more) or overweight and at least one weight-related comorbidity - APRICUS